



November 12, 2020.

To
The General Manager
Dept. of Corporate Services – CRD
The Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Sub: Outcome of the Board Meeting Dt. 12-11-2020

Ref: Regulation 30 & 33 of the SEBI (LODR) Regulations, 2015.

Unit: Godavari Drugs Limited – Script Code (530317).

Dear Sir,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors of the Company at its meeting held today at 03.00 p.m through Video Conferencing and concluded at 04:20 p.m inter alia transacted the following business:

1. Un audited financial results for the quarter and half year ended ended 30th September, 2020 were considered, reviewed and adopted by the Board of Directors of the Company along with the Limited Review Report.
2. The Board of Directors discussed and taken note of the Compliance Report placed before the Board, with regard to compliances under the various applicable laws, Acts and Regulation.

The meeting concluded at 04:20 p.m.

For Godavari Drugs Limited

M. Narandeni
Narendra Maddineni
Company Secretary &
Compliance Officer



GODAVARI DRUGS LIMITED

CIN NO.L24230TG1987PLC008016

Regd. Office : - "Mayfair", S.P.Road, Secunderabad.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2020

(Rs. In Lakhs)

| Sl. No. | Particulars | Quarter ended | | | Half Year ended | | Year ended |
|---------|---|----------------|----------------|----------------|-----------------|----------------|----------------|
| | | 30.09.2020 | 30.06.2020 | 30.09.2019 | 30.09.2020 | 30.09.2019 | 31.03.2020 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Revenue from operations | 3092.03 | 2569.22 | 2307.24 | 5661.25 | 4534.92 | 9569.77 |
| 2 | Other Income | 20.50 | 0.93 | 0.54 | 21.43 | 7.91 | 32.77 |
| 3 | Total Revenue from operations (1+2) | 3112.53 | 2570.15 | 2307.78 | 5682.68 | 4542.83 | 9602.54 |
| 4 | Expenses | | | | | | |
| | (a) Cost of materials consumed | 2488.37 | 2385.4 | 1495.41 | 4873.77 | 3783.96 | 7738.19 |
| | (b) Changes in inventories of finished goods & work-in-progress | -13.28 | -395.73 | 345.12 | -409.01 | -196.09 | -71.11 |
| | (c) Employee benefits expense | 89.57 | 77.78 | 80.60 | 167.35 | 163.86 | 344.51 |
| | (d) Depreciation & amortization expense | 28.13 | 27.85 | 29.48 | 55.98 | 58.68 | 116.26 |
| | (e) Finance Costs | 83.17 | 84.88 | 67.62 | 168.05 | 135.80 | 291.15 |
| | (f) Other Expenses | 284.95 | 275.06 | 245.96 | 560.01 | 489.02 | 954.65 |
| | Total expenses | 2960.91 | 2455.24 | 2264.19 | 5416.15 | 4435.23 | 9373.65 |
| 5 | Profit before exceptional Items and tax (3-4) | 151.62 | 114.91 | 43.59 | 266.53 | 107.60 | 228.89 |
| 6 | Exceptional items | | | | - | - | - |
| 7 | Profit before Tax (5-6) | 151.62 | 114.91 | 43.59 | 266.53 | 107.60 | 228.89 |
| 8 | Tax expense | 52.78 | 29.84 | 16.39 | 82.62 | 37.12 | 28.82 |
| 9 | Net Profit for the period (7-8) | 98.84 | 85.07 | 27.20 | 183.91 | 70.48 | 200.07 |
| 10 | Other Comprehensive Income | | | | | | |
| | (i) Items that will not be reclassified to profit or loss | | | | - | - | - |
| | (ii) Income tax relating to Items that will not be reclassified to profit or loss | | | | - | - | - |
| | (iii) Items that will be reclassified to profit or loss-- | | | | - | - | - |
| | Income tax relating to Items that will be reclassified | | | | - | - | - |
| | (iv) to profit or loss | | | | - | - | - |
| | Total Other Comprehensive Income (Net of Tax) | | | | - | - | - |
| 11 | Total Comprehensive Income (9+10) | 98.84 | 85.07 | 27.20 | 183.91 | 70.48 | 200.07 |
| 12 | Paid-up equity share capital (Face Value Rs. 10/- per share) | 753.05 | 753.05 | 753.05 | 753.05 | 753.05 | 753.05 |
| 13 | Other Equity | | | | | | 1272.76 |
| 14 | Earnings per share (of Rs.10/- each) (not annualized) | | | | | | |
| | (a) Basic | 1.31 | 1.13 | 0.36 | 2.44 | 0.94 | 2.66 |
| | (b) Diluted | 1.31 | 1.13 | 0.36 | 2.44 | 0.94 | 2.66 |

- Notes:
- The above results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at their meeting held on November 12, 2020.
 - The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
 - The Limited Review by the Statutory Auditors for the quarter ended as required under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been received.
 - Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

K.K.Jain

K.K.Jain
Director Finance
DIN: 00076657



Place: Secunderabad
Date: 12-11-2020

GODAVARI DRUGS LIMITED
CIN NO.L24230TG1987PLC008016
Regd. Office : - "Mayfair", S.P.Road, Secunderabad.
Statement of Assets and Liabilities

(Rs. In Lakhs)

| Particulars | Half Year ended | Year ended |
|--|-----------------|----------------|
| | (30.09.2020) | (31.03.2020) |
| | (Unaudited) | (Audited) |
| ASSETS | | |
| 1. Non - current assets | | |
| a. Property, plant and equipment | 1325.38 | 1381.36 |
| b. Capital work - in -progress | 928.4 | 892.95 |
| c. Investment Property | | |
| d. Goodwill | | |
| e. Other Intangible assets | | |
| f. Intangible assets under development | | |
| g. Biological Assets other than bearer plants | | |
| h. Financial Assets | | |
| (i) Investments | 0.01 | 0.01 |
| (ii) Trade Receivables | | |
| (iii) Loans | | |
| (iv) Others | | |
| i. Deferred tax assets (net) | | |
| j. Other non-current assets | 34.86 | 34.55 |
| 2. Current assets | | |
| (a) Inventories | 1712.14 | 1775.20 |
| (b) Financial Assets | | |
| (i) Investments | | |
| (ii) Trade Receivables | 3828.12 | 3601.85 |
| (iii) Cash and cash equivalents | 205.13 | 142.66 |
| (iv) Bank balances other than (iii) above | | |
| (v) Loans | 58.06 | 49.48 |
| (vi) Others | | |
| (c) Current Tax Assets (Net) | | |
| (d) Other current assets | 529.96 | 513.55 |
| Total Assets | 8622.06 | 8391.61 |
| EQUITY AND LIABILITIES | | |
| EQUITY | | |
| (a) Equity Share capital | 753.05 | 753.05 |
| (b) Other Equity | 1456.66 | 1272.76 |
| (i) Reserves and surplus | | |
| Non controlling interest | | |
| LIABILITIES | | |
| 1. Non - current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 1636.65 | 1116.36 |
| (ii) Trade payables | | |
| (iii) Other financial liabilities (other than those specified in item (b)) | | |
| (b) Provisions | 73.10 | 67.09 |
| (c) Deferred tax liabilities (Net) | 104.75 | 57.48 |
| (d) Other non-current liabilities | | |
| 2. Current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 1281.38 | 1491.18 |
| (ii) Trade payables | 2690.27 | 3027.28 |
| (iii) Other financial liabilities (other than those specified in item (c)) | 551.84 | 567.41 |
| (b) Other current liabilities | | |
| (c) Provisions | 39 | 39.00 |
| (d) Current Tax Liabilities (Net) | 35.36 | |
| Total Equity and Liabilities | 8622.06 | 8391.61 |

For GODAVARI DRUGS LIMITED

K.K.Jain
K.K.Jain

Director Finance
DIN: 00076657



Place: Secunderabad
Date : 12.11.2020

12/11/20
to be checked

Godavari Drugs Limited
Cash Flow Statement for the Half Year ended September 30,2020.

Rupees In Lakhs

| Particulars | As on 30.09.2020 | As on 31.03.2020 |
|---|------------------|------------------|
| A. Cash Flow from Operating Activities | | |
| Profit before Depreciation, Interest and Tax | 490.56 | 636.60 |
| Other income considered separately | 21.43 | (32.77) |
| Net | 469.13 | 603.83 |
| (Increase) / Decrease in Inventories | 63.05 | (128.41) |
| (Increase) / Decrease in Receivables | -226.27 | (206.29) |
| (Increase) / Decrease in Short term Loans & Advances | -8.58 | (8.64) |
| (Increase) / Decrease in Other Current Assets | -16.41 | -99.87 |
| Increase / (Decrease) in Current Liabilities | -562.38 | 503.03 |
| Less: Income tax paid | | (28.82) |
| Less: Deferred Tax Adjustment | | (10.18) |
| Total A | -281.46 | 624.65 |
| B. Cash Flow from Investing Activities | | |
| Increase in Fixed Assets and Capital WIP | -35.46 | (688.94) |
| Increase in Non Current Assets | -0.30 | (11.84) |
| Other Income | 21.43 | 32.77 |
| Total B | -14.33 | (668.01) |
| C. Cash Flow from Financing Activities | | |
| Increase / (Decrease) in Long Term Borrowings | 520.29 | 315.15 |
| Increase / (Decrease) in Long Term Provisions | 6.01 | 9.73 |
| Increase / (Decrease) in Long Term Advances | | |
| Interest Paid | -168.05 | (291.15) |
| Total C | 358.25 | 33.73 |
| D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C] | 62.47 | (9.93) |
| Cash and cash equivalents at the beginning of the year (01.04.2020) | 142.66 | 152.59 |
| Cash and cash equivalents at the end of the year (30.09.2020) | 205.13 | 142.66 |
| Increase/(-)Decrease | 62.47 | (9.93) |

For and on behalf of the Board of Directors

K. K. Jain

Kirti Kumar Jain
Director Finance

